Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA released this week a final guidance on anticounterfeiting excipients. The guidance recommends that any physical–chemical identifier incorporated into solid oral dosage forms of drugs be pharmacologically inactive. Quality, potency, and bioavailability are also discussed.

FDA, the Centers for Medicare (CMS), and Medicaid launched a pilot program last week to conduct parallel reviews of medical devices, which are seeking FDA approval as well as Medicare coverage. “The FDA and CMS anticipate that parallel review will facilitate the development of innovative new products and increase the efficiency of the review processes for both agencies,” according to an agency press release. The two-year pilot is voluntary and will not change the existing separate and distinct review standards for FDA device approval and CMS coverage determination.

FDA also announced a joint study with NIH on tobacco use and risk. The large-scale, national study will monitor tobacco users to assess the behavioral and health impacts of new government tobacco regulations, namely the 2009 Family Smoking Prevention and Tobacco Control.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here